Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmaus Life SciencesEMMA Earnings per Share (Diluted) is $-0.13 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 1,166 Biotechnology companies, Emmaus Life Sciences ranks better than 58.75% on this metric.
Emmaus Life Sciences's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.13.
During the past 3 years, the average EPS without NRIGrowth Rate was 23.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 7.30% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 51.00% per year.
During the past 13 years, Emmaus Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 81.70% per year. The lowest was -545.80% per year. And the median was 20.40% per year.
Emmaus Life Sciences (OTCPK:EMMA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Emmaus Life Sciences Earnings per Share (Diluted) Related Terms
Emmaus Life Sciences Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences Earnings per Share (Diluted) Chart
EMMA vs AGTX, BZYR, ATXI: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's PE Ratio falls into.
Emmaus Life Sciences Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Emmaus Life Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.13 mean?
Emmaus Life Sciences (EMMA) has a Earnings per Share (Diluted) of $-0.13 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #481 out of 1166 companies in the Biotechnology industry, placing it in the top 41.3%.
Is Emmaus Life Sciences' Earnings per Share (Diluted) too high?
Emmaus Life Sciences' current Earnings per Share (Diluted) is $-0.13. Based on the distribution chart, Emmaus Life Sciences ranks #481 out of 1166 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' Earnings per Share (Diluted) compare to AGTX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #481 out of 1166 companies for Earnings per Share (Diluted). This puts Emmaus Life Sciences in the upper half of its industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Earnings per Share (Diluted) is $-0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Earnings per Share (Diluted) is $-0.13. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Earnings per Share (Diluted) is $-0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 
